Orchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative Optimism

Stock Information for Fractyl Health, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fractyl Health, Inc.

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Announces Results for the First Quarter of 2025
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
Anteris Reports 2024 Financial Results and Provides Corporate Update
Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays
Anteris Technologies Announces First Successful Implantation of DurAVR(TM) THV in a Valve-in-Valve Procedure

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.